1.1000
25-November-24 13:18:11
15 minutes delayed
Stocks
+0.0200
+1.85%
Today's range
1.0600 - 1.1200
ISIN
N/A
Source
NASDAQ
Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
12 Jan 2021 07:05:00 By Nasdaq GlobeNewswire
Clearside Biomedical Announces Pricing of $12 Million Registered Direct Offering
06 Jan 2021 07:05:00 By Nasdaq GlobeNewswire